drugset
drugset / Trial / NCT04669262

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

NCT04669262 ↗

Phase 1 Completed 25 enrolled BeiGene
RandomizedSequentialDouble-blindBasic science

Summary

The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants

Timeline

Start
2020-12-09
Primary completion
2021-05-21
Completion
2021-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BGB-DXP593 Monoclonal antibody — Intravenous
Subject BGB-DXP604 Unknown — Intravenous

Indications

No indication recorded.